. Author manuscript; available in PMC: 2015 Jan 27.

Published in final edited form as: Int J Endocr Oncol. 2014;1(2):173–182. doi: 10.2217/ije.14.13

Table 1.

Clinical trials that are actively recruiting patients with adrenocortical carcinoma.

Clinical trial	NCT number	Primary outcome
Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma	NCT01833832	Intraperitoneal progressionfree survival
Phase I Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma	NCT01898715	Determine dose-limiting toxicity and maximum-tolerated dose
A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma	NCT01832974	Maximum-tolerated dose and objective response in Phase I, progression free survival in Phase II
A Phase I/II Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors	NCT01262235	Determine dose-limiting toxicity, maximum-tolerated dose and antitumor activity
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence (ADIUVO trial)^†	NCT00777244	Disease-free survival

^†

European trial – no sites available in the USA.